Abstract
The therapeutic effects of immunosuppressive agents such as cyclosporin A, mycophenolate mofetil, rituximab and sirolimus on primary focal segmental glomerulosclerosis (FSGS) remain controversial. The present study was intended to review and analyze the treatment results of immunosuppressive agents for primary FSGS in child and adult patients. Complete remission rates and partial remission rates were extracted from published articles and analyzed using statistical tests. Cyclosporin A was effective in the treatment of child and adult patients with idiopathic FSGS. Rituximab therapy displayed a higher complete remission and partial remission rate in children than in adult FSGS patients. Multiple-center large-scale rigorous trials should be considered to evaluate the risk-benefit ratio of immunosuppressive treatment in patients with primary FSGS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
